Tumor drug resistance specialist Deciphera Pharmaceuticals (Nasdaq: DCPH) has inked a deal with Shanghai-based Zai Lab (Nasdaq: ZLAB) to advance the development and commercialization of ripretinib in China.
Ripretinib is an investigational KIT and PDGFRα kinase switch control inhibitor, in clinical development for the treatment of cancers driven in this way.
Under the terms of the deal, East Coast, USA-based Deciphera will be paid $20 million, and up to $185 million in potential development and commercial milestones, plus royalties on sales in China, Hong Kong, Macau and Taiwan.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze